Popular Trials
Behavioural Intervention
Psychological Well-being Intervention for Healthcare Worker Burnout During COVID-19
This trial will assess the effectiveness of an online psychological well-being intervention (PARK) in reducing stress and associated-burnout, absenteeism, and intentions to leave the workforce in a subset of 750 persons who have been participating in a study of healthcare workers at Northwestern Medicine (NM) since Spring 2020.
mRNA Vaccine
mRNA COVID-19 Vaccines Safety for Previous Vaccine Reactions
This trial is being conducted to see if people who have had bad reactions to COVID-19 vaccines in the past can safely have another dose, or if people with a history of allergies can safely have the vaccine at all.
Behavioral Intervention
Stepped Alcohol Intervention for Alcohol-related Liver Disease
This trial is testing a new way to help people with chronic liver disease who have unhealthy alcohol use. The new treatment includes 3 sessions of motivational interviewing, and referral to addiction medicine if necessary. The trial will measure how well the new treatment works at 6 and 12 months.
Behavioral Intervention
Physical activity +1 More for Coronavirus
This trial aims to find efficient treatments to help those with chemosensory losses due to Coronavirus disease (COVID-19). 75 participants will be recruited and randomly assigned to one of three groups: physical activity, smell training, or control. The groups will engage in their assigned activities for 12 weeks and be assessed at the beginning, end, and 12 weeks after the end of the intervention period.
Popular Filters
Trials for COVID-19 Patients
Virus Therapy
Polio Vaccine (IPV) for COVID-19
A total of 300 healthy volunteers between the ages of 18 and 80 with no previous history of COVID-19 will be entered into the study and will receive IPV by injection on Day 1. Blood specimens collected pre-inoculation will be tested for cross-reactivity to poliovirus and SARS-CoV-2 by Western blot. An additional specimen will be collected on Day 28 post-inoculation and, likewise tested for cross-reactivity to poliovirus and SARS-CoV-2. The number of subjects with an immune response to SARS-CoV-2 antigens following inoculation with IPV will be summarized.
Virus Therapy
CoVLP for COVID-19
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile. The Phase 3 portion is an event-driven, randomized, observer blinded, placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation compared to placebo. Subjects will be followed for safety and immunogenicity for a period of 12 months after the last vaccination.
Virus Therapy
COVID 19 Convalescent Plasma for Coronavirus
This pilot, prospective study will assess the safety and efficacy of COVID-19 convalescent plasma versus standard care as treatment for severe and/or critical COVID-19 (as defined in the inclusion criteria) in adults 18 years of age and older. A total of 350 eligible subjects will receive a transfusion of anti-SARS-CoV2 ( severe acute respiratory syndrome) convalescent plasma.
Anti-metabolites
Decitabine for COVID-19
This trial tests if the drug decitabine can safely and effectively treat severe lung issues in critically ill COVID-19 patients. Patients will receive either decitabine or standard care. The goal is to see if decitabine helps improve their condition by reducing lung damage.
Trials for Acute Respiratory Distress Syndrome Patients
Monoclonal Antibodies
EB05 for Hospitalized COVID-19 Patients
This trial is testing a potential new treatment, EB05, for people who have been hospitalized with COVID-19. The treatment is designed to target the initial step in the signalling pathways of these DAMPs in innate immunity.
Pneumatic Device
V/Q System for Acute Respiratory Distress Syndrome in COVID-19
This trial tests a special Vest that helps COVID-19 patients with severe lung issues breathe better. The Vest inflates and deflates to improve oxygen levels in the blood. It aims to provide a safer and simpler alternative to turning patients onto their stomachs.
Phase 3 Trials
Virus Therapy
CoVLP for COVID-19
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile. The Phase 3 portion is an event-driven, randomized, observer blinded, placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation compared to placebo. Subjects will be followed for safety and immunogenicity for a period of 12 months after the last vaccination.
Immunoglobulin
hIVIG for COVID-19
This trial is for people with recently diagnosed SARS-CoV-2 infection who do not require hospitalization. The goal is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo.
Virus Therapy
DAS181 for Respiratory Infections
This trial will enroll immunocompromised patients with Lower Tract parainfluenza infection to study the safety and efficacy of an investigational vaccine. A sub-study will also enroll patients with severe COVID-19.
Trials With No Placebo
Virus Therapy
Polio Vaccine (IPV) for COVID-19
A total of 300 healthy volunteers between the ages of 18 and 80 with no previous history of COVID-19 will be entered into the study and will receive IPV by injection on Day 1. Blood specimens collected pre-inoculation will be tested for cross-reactivity to poliovirus and SARS-CoV-2 by Western blot. An additional specimen will be collected on Day 28 post-inoculation and, likewise tested for cross-reactivity to poliovirus and SARS-CoV-2. The number of subjects with an immune response to SARS-CoV-2 antigens following inoculation with IPV will be summarized.
Virus Therapy
COVID 19 Convalescent Plasma for Coronavirus
This pilot, prospective study will assess the safety and efficacy of COVID-19 convalescent plasma versus standard care as treatment for severe and/or critical COVID-19 (as defined in the inclusion criteria) in adults 18 years of age and older. A total of 350 eligible subjects will receive a transfusion of anti-SARS-CoV2 ( severe acute respiratory syndrome) convalescent plasma.
Trials Offering Remuneration
Virus Therapy
Trivalent Coronavirus Vaccine VBI-2901a for COVID-19
This trial tests a new vaccine, VBI-2901a, aimed at protecting against three coronaviruses, including COVID-19. It targets adults aged 18 to 64 who have previously been vaccinated. The vaccine works by using virus-like particles to boost the immune system's response.
Virus Therapy
mRNA Vaccine Doses for COVID-19
This trial is testing a new COVID-19 vaccine on healthy adults who have already been vaccinated. The goal is to see if it can safely boost their immune response. The vaccine works by using genetic material to help the body recognize and fight the virus.
Mushroom-based Product
Mushroom-based Product for COVID-19
This trial will compare two types of mushrooms to see if they help treat mild-to-moderate symptoms of COVID-19 in people who are self-quarantining at home. A total of 66 people will be in the study.
View More Related Trials
Frequently Asked Questions
Introduction to coronavirus
What are the top hospitals conducting coronavirus research?
As the world continues to grapple with the ongoing COVID-19 pandemic, hospitals are playing a crucial role in conducting clinical trials to find effective treatments and vaccines. Among these institutions is the University of Michigan in Ann Arbor, which has embarked on two active coronavirus trials, marking an important step forward in combating this global crisis. Having recorded its first trial in 2020, the university is dedicated to exploring innovative approaches to tackle the virus head-on. Meanwhile, Grady Health System in Atlanta has one ongoing coronavirus trial underway. While they may not have conducted any previous trials specifically focused on COVID-19, their involvement signifies their commitment to contribute towards finding solutions for this unprecedented health challenge.
In Atlanta itself, other hospitals are also actively engaged in advancing our understanding of and response to COVID-19. Emory University Hospital Midtown has initiated one current coronavirus trial along with having accomplished a single prior investigation since recording its inaugural coronavirus trial in 2020. Similarly, Emory Hospital and Metro-Atlanta each have one active coronavirus trial but do not possess any completed trials at present.
These hospitals’ dedication demonstrates their pivotal roles as centers of research and innovation during these challenging times. Through rigorous scientific exploration and collaboration among medical professionals across diverse locations like Ann Arbor and Atlanta alike, progress is made toward identifying strategies that will ultimately help us overcome this devastating global pandemic together
Which are the best cities for coronavirus clinical trials?
When it comes to coronavirus clinical trials, several cities emerge as leaders in research and development. Atlanta, Georgia, Houston, Texas, Toronto, Ontario, New york City, and Washington D.C. are among the top locations with active trials. These cities offer individuals access to studies focusing on various treatments such as LDN Treatment Arm and 9vHPV Vaccine in Atlanta; Niclosamide and 700mg Leronlimab in Houston; VBI-2901a and Aspirin Treatment in Toronto; Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) and Stress First Aid in New York City; Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)and 9vHPV Vaccine in Washington D.C. By conducting these trials across different regions, researchers aim to advance our understanding of potential treatment options for COVID-19.
Which are the top treatments for coronavirus being explored in clinical trials?
The race to find effective treatments for the coronavirus continues, with several promising options emerging in clinical trials. Leading the pack is VBI-2901a, currently being tested in one active trial dedicated to fighting this global pandemic. Another contender gaining attention is the 9vHPV vaccine, also undergoing evaluation in one ongoing coronavirus trial. Baricitinib completes the lineup as a potential treatment option, with two all-time trials and one active trial focused on combatting COVID-19 since its first listing in 2020. These innovative therapies offer hope for a brighter future amidst these challenging times.
What are the most recent clinical trials for coronavirus?
Recent clinical trials for coronavirus offer promising prospects in the fight against this global pandemic. These include innovative approaches such as intravenously delivered MSC-exosomes, which are administered every other day on an escalating dose to combat the virus. Additionally, the mRNA-CR-04 vaccine has shown potential in early-phase trials, providing hope for effective immunization strategies. Another trial examines azeliragon's efficacy as a treatment option through its progression from Phase 2 to Phase 3 studies. Furthermore, the mRNA-1045 Dose Level B and VBI-2901a have both entered Phase 1 trials, demonstrating ongoing efforts to discover new therapeutic interventions against coronavirus infection. These cutting-edge clinical investigations signify significant advancements in our collective battle against COVID-19.
What coronavirus clinical trials were recently completed?
Several significant clinical trials for coronavirus have recently reached completion, showcasing the relentless efforts to combat this global health crisis. Notably, in August 2021, Merck Sharp & Dohme Corp. concluded a trial investigating the potential of Molnupiravir as a treatment option. Around the same time, Janssen Vaccines & Prevention B.V.'s trial on Ad26.COV2.S came to an end, examining its efficacy as a vaccine candidate. Additionally, research led by James L. Kirkland explored Fisetin's potential against COVID-19 and was completed in July 2021. These trials represent critical steps forward in our ongoing battle against the pandemic and demonstrate the dedication of researchers worldwide towards finding effective solutions.